We found a significant upregulation of DSG2 in patients with lung adenocarcinoma (LUAD), cervical squamous cell carcinoma (CESC), and pancreatic adenocarcinoma (PAAD) (Figure S5F, Supporting Information), which negatively associates with patients’ overall survival ratio (Figure S6A, Supporting Information). Here, DSG2 is linked to pancreatic adenocarcinoma.